Parabilis Medicines, Inc. (PBLS)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income	-209.71M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About PBLS

Parabilis Medicines is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines. Our lead product candidate, zolucatetide, is, to our knowledge, the first and only invest...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: PBLS
• Website: https://parabilismed.com/

Financial Performance

Financial numbers in USD